The Effect of Transjugular Intraheptic Portosystemic Shunt (TIPS) on Gastrointestinal Motility and the Gut Microbiota
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10016
- NYU Langone Health
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with either radiographic or biopsy proven decompensated cirrhosis (as determined by ascites, variceal hemorrhage, encephalopathy or jaundice).
- Patients undergoing an elective TIPS for any standard of care established indication (examples: worsening ascites, recurrent variceal bleeding).
Exclusion Criteria:
- Pregnant women.
- Patients unwilling or unable to provide informed consent.
- Patients undergoing an emergent TIPS for acute or subacute variceal hemorrhage.
- Patients with diabetes, significant cardiovascular, renal or other chronic disease which has been known to affect intestinal motility.
- Previously diagnosed gastroparesis or other GI dysmotility disorder.
- Patients currently taking narcotics, antibiotics excluding rifaximin, prokinetic medications or lactulose.
- Patients with a history of gastric bezoar.
- Patients with a history of multiple intestinal surgeries or GI surgery within the past 3 months.
- Patients with a history of gastrointestinal strictures, fistulas, or physiological or mechanical obstruction.
- Patients with a history of gastrointestinal strictures, fistulas, or physiological or mechanical obstruction.
- Patients with a history of gastrointestinal strictures, fistulas, or physiological or mechanical obstruction.
- Patients with a history of diverticulitis.
- Patients with swallowing disorders and increased risk of aspiration (such as prior history of aspiration).
- Patient with Celiac disease.
- Patients with implanted or portable electro-mechanical medical devices.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Cirrhosis Patients
10 Patients with body mass index (BMI) etiology of cirrhosis
|
Assessment of motility with Smart Pill, which will be read and confirmed by gastroenterologist trained to interpret motility studies
Assessment of motility with Smart Pill, which will be read and confirmed by gastroenterologist trained to interpret motility studies
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pre-TIPS intestinal transit time (measured in hours and minutes), via smart pill in patients with cirrhosis
Time Frame: 14 Weeks
|
Due to small sample size, Wilcoxon rank-sum test will be used to compare the continuous variable of gut transit times.
A p-value of <0.05 will be considered statistically significant.
|
14 Weeks
|
|
Post TIPS intestinal transit time (measured in hours and minutes), via smart pill in patients with cirrhosis
Time Frame: 14 Weeks
|
Due to small sample size, Wilcoxon rank-sum test will be used to compare the continuous variable of gut transit times.
A p-value of <0.05 will be considered statistically significant.
|
14 Weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Bedros Taslakian, MD, EBIR, NYU Langone Health
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 16-01360
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.